Candidíase (Portuguese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Candidíase" in Portuguese language version.

refsWebsite
Global rank Portuguese rank
4th place
8th place
218th place
177th place
2nd place
4th place
1st place
1st place
719th place
598th place
low place
823rd place
102nd place
459th place
1,989th place
1,732nd place
1,581st place
1,235th place
207th place
589th place
low place
low place

cdc.gov

doi.org

dx.doi.org

  • Abad CL, Safdar N (junho de 2009). «The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review.». Journal of chemotherapy (Florence, Italy). 21 (3): 243–52. PMID 19567343. doi:10.1179/joc.2009.21.3.243 
  • Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD (2016). «Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America». Clin. Infect. Dis. 62 (4): 409–417. PMID 26810419. doi:10.1093/cid/civ1194 
  • Patil S, Rao RS, Majumdar B, Anil S (dezembro de 2015). «Clinical Appearance of Oral Candida Infection and Therapeutic Strategies». Frontiers in Microbiology. 6. 1391 páginas. PMC 4681845Acessível livremente. PMID 26733948. doi:10.3389/fmicb.2015.01391Acessível livremente 
  • Martins N, Ferreira IC, Barros L, Silva S, Henriques M (junho de 2014). «Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment» (PDF). Mycopathologia. 177 (5–6): 223–40. PMID 24789109. doi:10.1007/s11046-014-9749-1. hdl:10198/10147Acessível livremente. Consultado em 24 de setembro de 2019. Cópia arquivada (PDF) em 17 de agosto de 2017. Candida species and other microorganisms are involved in this complicated fungal infection, but Candida albicans continues to be the most prevalent. In the past two decades, it has been observed an abnormal overgrowth in the gastrointestinal, urinary and respiratory tracts, not only in immunocompromised patients but also related to nosocomial infections and even in healthy individuals. There is a wide variety of causal factors that contribute to yeast infection which means that candidiasis is a good example of a multifactorial syndrome. 
  • Wang ZK, Yang YS, Stefka AT, Sun G, Peng LH (abril de 2014). «Review article: fungal microbiota and digestive diseases». Alimentary Pharmacology & Therapeutics. 39 (8): 751–66. PMID 24612332. doi:10.1111/apt.12665Acessível livremente. In addition, GI fungal infection is reported even among those patients with normal immune status. Digestive system-related fungal infections may be induced by both commensal opportunistic fungi and exogenous pathogenic fungi. The IFI in different GI sites have their special clinical features, which are often accompanied by various severe diseases. Although IFI associated with digestive diseases are less common, they can induce fatal outcomes due to less specificity of related symptoms, signs, endoscopic and imaging manifestations, and the poor treatment options. ... Candida sp. is also the most frequently identified species among patients with gastric IFI. ... Gastric IFI is often characterised by the abdominal pain and vomiting and with the endoscopic characteristics including gastric giant and multiple ulcers, stenosis, perforation, and fistula. For example, gastric ulcers combined with entogastric fungal infection, characterised by deep, large and intractable ulcers,[118] were reported as early as the 1930s. ... The overgrowth and colonisation of fungi in intestine can lead to diarrhoea. 
  • Erdogan A, Rao SS (abril de 2015). «Small intestinal fungal overgrowth». Current Gastroenterology Reports. 17 (4). 16 páginas. PMID 25786900. doi:10.1007/s11894-015-0436-2. Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent studies showed that 26 % (24/94) and 25.3 % (38/150) of a series of patients with unexplained GI symptoms had SIFO. The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea, and gas. The underlying mechanism(s) that predisposes to SIFO is unclear but small intestinal dysmotility and use of proton pump inhibitors has been implicated. However, further studies are needed; both to confirm these observations and to examine the clinical relevance of fungal overgrowth, both in healthy subjects and in patients with otherwise unexplained GI symptoms. ... For routine SIFO in an immunocompetent host, a 2–3 week oral course of fluconazole 100–200 mg will suffice. 
  • Fidel PL (2002). «Immunity to Candida». Oral Diseases. 8 (Suppl 2): 69–75. PMID 12164664. doi:10.1034/j.1601-0825.2002.00015.x 
  • Pappas PG (setembro de 2006). «Invasive candidiasis». Infectious Disease Clinics of North America. 20 (3): 485–506. PMID 16984866. doi:10.1016/j.idc.2006.07.004 
  • Mukherjee PK, Sendid B, Hoarau G, Colombel JF, Poulain D, Ghannoum MA (fevereiro de 2015). «Mycobiota in gastrointestinal diseases». Nature Reviews. Gastroenterology & Hepatology. 12 (2): 77–87. PMID 25385227. doi:10.1038/nrgastro.2014.188 
  • Santelmann H, Howard JM (janeiro de 2005). «Yeast metabolic products, yeast antigens and yeasts as possible triggers for irritable bowel syndrome» (PDF). European Journal of Gastroenterology & Hepatology. 17 (1): 21–6. CiteSeerX 10.1.1.567.6030Acessível livremente. PMID 15647635. doi:10.1097/00042737-200501000-00005. Consultado em 24 de outubro de 2017. Arquivado do original (PDF) em 5 de dezembro de 2019 
  • Collins SM (agosto de 2014). «A role for the gut microbiota in IBS». Nature Reviews. Gastroenterology & Hepatology. 11 (8): 497–505. PMID 24751910. doi:10.1038/nrgastro.2014.40 
  • Gouba N, Drancourt M (2015). «Digestive tract mycobiota: a source of infection». Médecine et Maladies Infectieuses. 45 (1–2): 9–16. PMID 25684583. doi:10.1016/j.medmal.2015.01.007Acessível livremente 

handle.net

hdl.handle.net

jptwellnesscircle.com

medlineplus.gov

medscape.com

emedicine.medscape.com

nhs.uk

nih.gov

ncbi.nlm.nih.gov

  • Jurden L, Buchanan M, Kelsberg G, Safranek S (junho de 2012). «Clinical inquiries. Can probiotics safely prevent recurrent vaginitis?». The Journal of family practice. 61 (6): 357, 368. PMID 22670239 
  • Abad CL, Safdar N (junho de 2009). «The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review.». Journal of chemotherapy (Florence, Italy). 21 (3): 243–52. PMID 19567343. doi:10.1179/joc.2009.21.3.243 
  • Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD (2016). «Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America». Clin. Infect. Dis. 62 (4): 409–417. PMID 26810419. doi:10.1093/cid/civ1194 
  • Walsh TJ, Dixon DM (1996). «Deep Mycoses». In: Baron S, et al. Baron's Medical Microbiology 4th ed. [S.l.]: Univ of Texas Medical Branch. ISBN 978-0-9631172-1-2. PMID 21413276. Cópia arquivada em 1 de dezembro de 2008 
  • Patil S, Rao RS, Majumdar B, Anil S (dezembro de 2015). «Clinical Appearance of Oral Candida Infection and Therapeutic Strategies». Frontiers in Microbiology. 6. 1391 páginas. PMC 4681845Acessível livremente. PMID 26733948. doi:10.3389/fmicb.2015.01391Acessível livremente 
  • Martins N, Ferreira IC, Barros L, Silva S, Henriques M (junho de 2014). «Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment» (PDF). Mycopathologia. 177 (5–6): 223–40. PMID 24789109. doi:10.1007/s11046-014-9749-1. hdl:10198/10147Acessível livremente. Consultado em 24 de setembro de 2019. Cópia arquivada (PDF) em 17 de agosto de 2017. Candida species and other microorganisms are involved in this complicated fungal infection, but Candida albicans continues to be the most prevalent. In the past two decades, it has been observed an abnormal overgrowth in the gastrointestinal, urinary and respiratory tracts, not only in immunocompromised patients but also related to nosocomial infections and even in healthy individuals. There is a wide variety of causal factors that contribute to yeast infection which means that candidiasis is a good example of a multifactorial syndrome. 
  • Wang ZK, Yang YS, Stefka AT, Sun G, Peng LH (abril de 2014). «Review article: fungal microbiota and digestive diseases». Alimentary Pharmacology & Therapeutics. 39 (8): 751–66. PMID 24612332. doi:10.1111/apt.12665Acessível livremente. In addition, GI fungal infection is reported even among those patients with normal immune status. Digestive system-related fungal infections may be induced by both commensal opportunistic fungi and exogenous pathogenic fungi. The IFI in different GI sites have their special clinical features, which are often accompanied by various severe diseases. Although IFI associated with digestive diseases are less common, they can induce fatal outcomes due to less specificity of related symptoms, signs, endoscopic and imaging manifestations, and the poor treatment options. ... Candida sp. is also the most frequently identified species among patients with gastric IFI. ... Gastric IFI is often characterised by the abdominal pain and vomiting and with the endoscopic characteristics including gastric giant and multiple ulcers, stenosis, perforation, and fistula. For example, gastric ulcers combined with entogastric fungal infection, characterised by deep, large and intractable ulcers,[118] were reported as early as the 1930s. ... The overgrowth and colonisation of fungi in intestine can lead to diarrhoea. 
  • Erdogan A, Rao SS (abril de 2015). «Small intestinal fungal overgrowth». Current Gastroenterology Reports. 17 (4). 16 páginas. PMID 25786900. doi:10.1007/s11894-015-0436-2. Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent studies showed that 26 % (24/94) and 25.3 % (38/150) of a series of patients with unexplained GI symptoms had SIFO. The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea, and gas. The underlying mechanism(s) that predisposes to SIFO is unclear but small intestinal dysmotility and use of proton pump inhibitors has been implicated. However, further studies are needed; both to confirm these observations and to examine the clinical relevance of fungal overgrowth, both in healthy subjects and in patients with otherwise unexplained GI symptoms. ... For routine SIFO in an immunocompetent host, a 2–3 week oral course of fluconazole 100–200 mg will suffice. 
  • Fidel PL (2002). «Immunity to Candida». Oral Diseases. 8 (Suppl 2): 69–75. PMID 12164664. doi:10.1034/j.1601-0825.2002.00015.x 
  • Pappas PG (setembro de 2006). «Invasive candidiasis». Infectious Disease Clinics of North America. 20 (3): 485–506. PMID 16984866. doi:10.1016/j.idc.2006.07.004 
  • «Thrush». 2011. Consultado em 8 de abril de 2011. Cópia arquivada em 10 de fevereiro de 2011 
  • Mukherjee PK, Sendid B, Hoarau G, Colombel JF, Poulain D, Ghannoum MA (fevereiro de 2015). «Mycobiota in gastrointestinal diseases». Nature Reviews. Gastroenterology & Hepatology. 12 (2): 77–87. PMID 25385227. doi:10.1038/nrgastro.2014.188 
  • Santelmann H, Howard JM (janeiro de 2005). «Yeast metabolic products, yeast antigens and yeasts as possible triggers for irritable bowel syndrome» (PDF). European Journal of Gastroenterology & Hepatology. 17 (1): 21–6. CiteSeerX 10.1.1.567.6030Acessível livremente. PMID 15647635. doi:10.1097/00042737-200501000-00005. Consultado em 24 de outubro de 2017. Arquivado do original (PDF) em 5 de dezembro de 2019 
  • Collins SM (agosto de 2014). «A role for the gut microbiota in IBS». Nature Reviews. Gastroenterology & Hepatology. 11 (8): 497–505. PMID 24751910. doi:10.1038/nrgastro.2014.40 
  • Gouba N, Drancourt M (2015). «Digestive tract mycobiota: a source of infection». Médecine et Maladies Infectieuses. 45 (1–2): 9–16. PMID 25684583. doi:10.1016/j.medmal.2015.01.007Acessível livremente 

psu.edu

citeseerx.ist.psu.edu

uminho.pt

repositorium.sdum.uminho.pt

web.archive.org